Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.60 |
| ▸ | MEN1 | O00255 | 5/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | NQO2 | P16083 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3241519 | 0.94 | ALDH1A1 (0.58) | ALDH1A1MEN1KMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL3245109 | 0.94 | ALDH1A1 (0.60) | ALDH1A1MEN1KMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL13293346 | 0.93 | ALDH1A1 (0.54) | ALDH1A1MEN1KMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL13293317 | 0.90 | ALDH1A1 (0.57) | ALDH1A1MEN1KMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL5502346 | 0.90 | ALDH1A1 (0.51) | ALDH1A1MEN1KMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL3245238 | 0.89 | MAPT (0.55) | ALDH1A1MEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL17507532 | 0.87 | ALDH1A1 (0.68) | ALDH1A1MEN1KMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL3247653 | 0.86 | ALDH1A1 (0.61) | ALDH1A1MEN1KMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL3244264 | 0.86 | RAB9A (0.67) | ALDH1A1MEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL3241186 | 0.86 | MEN1 (0.65) | ALDH1A1MEN1KMT2ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745490-B2 | Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies | PROTEOTECH, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745490-B2 | Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies | PROTEOTECH, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20090060838-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTEOTECH INC. | 2009-03-05 | — | — | US | disclosed |
| US-20090060838-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTEOTECH INC. | 2009-03-05 | — | — | US | disclosed |
| US-20090060838-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTEOTECH INC. | 2009-03-05 | — | — | US | disclosed |
| EP-1751097-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | Proteotech, Inc. (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20060199838-A1 | Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies | PROTAMED, INC. | 2006-09-07 | — | — | US | disclosed |
| WO-2005113489-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTEOTECH, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090060838-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | IAPP, SNCA, BACE2 | ALDH1A1 2612/4885MEN1 2528/4885KMT2A 1803/4885 |
| US-20060199838-A1 | Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies | IAPP, SNCA, BACE2 | ALDH1A1 2671/4885MEN1 3425/4885KMT2A 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.